ZW327 / Zymeworks - LARVOL DELTA

ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload (AACR 2025) - "The antibody binding, internalization and spheroid penetration were all superior to the hu9B12.v12 clinical benchmark antibody and ZW327 exhibited pronounced cytotoxicity when compared to DLYE5953A clinical benchmark ADC. A single administration of ZW327 resulted in tumor regression across xenograft models and demonstrated a favorable PK profile. Overall, these results support the potential of ZW327 as a novel therapeutic agent against Ly6E-bearing cancers."

Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • LY6E

ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload (GlobeNewswire) - "ZW327 demonstrated robust anti-tumor activity in low, mid, and high Ly6E-expressing cell line-derived xenograft (CDX) and PDX models. ZW327 maintains potential in diverse indications including NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, and gastrointestinal cancers, including pancreatic ductal adenocarcinoma; Across various tumor types, ZW327 exhibited favorable PK and tolerability in NHP at exposure levels above those projected to be efficacious; This promising preclinical activity highlights the potential to ZW327 as an innovative therapeutic option in Ly6E-expressing cancers."

Preclinical • Gastrointestinal Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer